Back to discover
Drug

Oxycodone

Approved · FDA
ClassMu opioid receptor agonistEmerging researchLate-stage development
Also known as (-)-14-Hydroxydihydrocodeinone, 14-hydroxydihydrocodeinone, Aspirin-Oxycodone, Combunox+43 more

(-)-14-Hydroxydihydrocodeinone, 14-hydroxydihydrocodeinone, Aspirin-Oxycodone, Combunox, Dazidox, Dihydro-14-hydroxycodeinone, Dihydrohydroxycodeinone, Dihydroxycodeinone, ETH-Oxydose, Endocet, Endocodone, Endodan, M-Oxy, Magnacet, Nalocet, Narvox, Oxaydo, Oxecta, Oxicodona, OxyCONTIN, Oxyfast, Percocet, Percodan, Percolone, Perloxx, Primalev, Primlev, Prolate, Roxicet, Roxicodone, Roxilox, Roxiprin, RoxyBond, Targiniq ER, Tylox, Xolox, Xtampza, 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, OxyCODONE Hydrochloride, Oxycodonum, Percocet 10/325, Percocet 10/650, Percocet 2.5/325, Percocet 5/325, Percocet 7.5/325, Percocet 7.5/500.

RxNorm7804ChEMBLCHEMBL656ATCN02AA05UNIICD35PMG570
2
Research papers
19
Active clinical trials
Mu-type opioid receptor
Primary target
29
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms

Clinical trial2026-07-31Primary completion · ClinicalTrials.gov

Multimodal Management for Perioperative Analgesia in Otolaryngology - Head and Neck Free Flap Reconstructive Surgery: A Prospective Study

Clinical trial2026-07-07Results posted · ClinicalTrials.gov

Neurobehavioral Mechanisms of Choice in Opioid Use Disorder

Clinical trial2026-07-02Results posted · ClinicalTrials.gov

Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Function in Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial

Clinical trial2026-06-25Results expected Q3 2026 · ClinicalTrials.gov

Supplemental approval: OXYCODONE (ANDA203638)

Regulatory2026-06-18FDA

Supplemental approval: OXYCODONE (NDA208090)

Regulatory2026-06-18FDA

Supplemental approval: OXYCODONE AND ACETAMINOPHEN (ANDA210644)

Regulatory2026-06-18FDA

A Randomized Control Trial for Opioid Use After Laparoscopic Salpingectomy

Clinical trial2026-06-03Results expected Q4 2026 · ClinicalTrials.gov

Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints

Clinical trial2026-06-03Results expected Q4 2026 · ClinicalTrials.gov

Label change: OXYCODONE (NDA208090)

Regulatory2025-12-22FDA

The Role of Acid-Sensing Ion Channel 1A (ASIC1A) in the Behavioral and Synaptic Effects of Oxycodone and Other Opioids.

Research2024-10-29International journal of molecular sciences

A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.

Research2010-09-01Pain practice : the official journal of World Institute of Pain

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Oxycodone
Aliases & brands
(-)-14-Hydroxydihydrocodeinone14-hydroxydihydrocodeinoneAspirin-OxycodoneCombunoxDazidoxDihydro-14-hydroxycodeinoneDihydrohydroxycodeinoneDihydroxycodeinoneETH-OxydoseEndocetEndocodoneEndodanM-OxyMagnacetNalocetNarvoxOxaydoOxectaOxicodonaOxyCONTINOxyfastPercocetPercodanPercolonePerloxxPrimalevPrimlevProlateRoxicetRoxicodoneRoxiloxRoxiprinRoxyBondTarginiq ERTyloxXoloxXtampza4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-oneOxyCODONE HydrochlorideOxycodonumPercocet 10/325Percocet 10/650Percocet 2.5/325Percocet 5/325Percocet 7.5/325Percocet 7.5/500
RxNorm CUI
7804
ChEMBL ID
CHEMBL656
ATC codes
N02AA05
UNII
CD35PMG570
Primary mechanism
Mu opioid receptor agonist
Regulatory jurisdictions
fda

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Mu-type opioid receptor
OPRM1 · P35372
AGONISTMu opioid receptor agonist

Regulatory timeline

29 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2014-06-03
Latest approval
2026-06-18
Authorities
FDA
Total events
29
fdaU.S. Food and Drug Administration· 29 events
2026-06-18Supplemental approval
Supplemental approval: OXYCODONE (ANDA203638)
Evidence ↗
2026-06-18Supplemental approval
Supplemental approval: OXYCODONE (NDA208090)
Evidence ↗
2026-06-18Supplemental approval
Supplemental approval: OXYCODONE AND ACETAMINOPHEN (ANDA210644)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

164 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
164
registered trials across all phases
LATEST COMPLETION 2025
19
Active studies
17
Recruiting
110
Late-stage (III+)
100
Completed
45
Discontinued
PHASE DISTRIBUTIONn = 164
Early Phase 18Phase 124Phase 1 / 25Phase 217Phase 2 / 31Phase 320Phase 465Phase N / A24

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty: A Prospective Randomized Controlled Trial

Enrolling by invitationPH IVMayo Clinicn=5602031

Successful Implementation of an Opioid Reduction Toolkit in Pancreatectomy Patients Significantly Decreases Number of Opioids Prescribed and Consumed

SuspendedPH IVThomas Jefferson Universityn=1592028

Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

Active, not recruitingPH IVBoston Children's Hospitaln=682027

Comparison of Suzetrigine and Oxycodone for Postoperative Pain and Analgesic Requirements After Primary Total Knee Arthroplasty: a Prospective, Randomized Study

Enrolling by invitationPH IVUniversity of Louisvillen=1402027

A Randomized Control Trial for Opioid Use After Laparoscopic Salpingectomy

RecruitingPH IVJohns Hopkins Universityn=382026

Recent completions

Trials that read out recently, adding to the completed evidence base.

Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures

CompletedPH IVMayo Clinicn=862025

Neurobehavioral Mechanisms of Choice in Opioid Use Disorder

CompletedPH IJoshua A. Lile, Ph.D.n=122025

Mitigating Rebound Pain Following Regional Anaesthesia for Ankle Fracture Surgery: a Three-armed Randomised Control Trial

CompletedPH IVUniversity College Corkn=1202025

Clinical Evaluation of NMDA Modulator NYX-783 for OUD: Randomized, Double-blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of NYX-783 in Combination With Oxycodone (Study 1)

CompletedPH IYale Universityn=92024

Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study

CompletedN/APeking University First Hospitaln=882024

Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing: an Exploratory Study in Healthy Volunteers (The Polo Study)

CompletedPH IVLeiden University Medical Centern=242024

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20102024
Major research themes5
Acid Sensing Ion Channels1Analgesics, Opioid1Mice, Knockout1Nucleus Accumbens1Oxycodone1
Journals, researchers & institutions
Top journals
  • International journal of molecular sciences1
  • Pain practice : the official journal of World Institute of Pain1
Leading researchers
  • Andrys NRR1
  • Binsfeld H1
  • Fan R1
  • Fuller MJ1
  • Ghobbeh A1
  • Gupta SC1
  • Kreple CJ1
  • Lalumiere RT1
Leading institutions
free-text, unnormalised
  • Department of Veterans Affairs Medical Center1
  • Iowa Neuroscience Institute1
  • Schmerz-Zentrum am St.Franziskus Hospital Ahlen1
  • University of Iowa1
  • University of Utah1
  • University of Wisconsin School of Medicine and Public Health1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.